Article thumbnail

Addition of Bevacizumab to XELOX Induction Therapy Plus Concomitant Capecitabine-Based Chemoradiotherapy in Magnetic Resonance Imaging–Defined Poor-Prognosis Locally Advanced Rectal Cancer: The AVACROSS Study

By Miguel Nogué, Antonieta Salud, Pilar Vicente, Antonio Arriví, José María Roca, Ferran Losa, José Ponce, María José Safont, Inmaculada Guasch, Isabel Moreno, Ana Ruiz and Carles Pericay

Abstract

The objective of the current study was to assess the efficacy and toxicity of adding bevacizumab to induction chemotherapy followed by preoperative bevacizumab-based chemoradiotherapy in patients with locally advanced rectal cancer. Addition of bevacizumab to induction chemotherapy and chemoradiotherapy is feasible, with impressive activity and manageable toxicity. However, caution is recommended regarding surgical complications

Topics: Gastrointestinal Cancer
Publisher: AlphaMed Press
OAI identifier: oai:pubmedcentral.nih.gov:3228198
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.